甲胺劫持AMPK-ERK1/2信号,触发致病性"选择陷"和胸腺缩
Yilin Qian1, Jingli Zhang1, Shengqiu Liu2
1Department of Pathogenic Biology and Immunology, Jiangsu Provincial Key Laboratory of Critical Care Medicine, School of Medicine, Southeast University, Nanjing, Jiangsu, China.
甲胺通过创建一个"选择陷",损害免疫恒常性,从而触发发小细胞亡. 这即使在低剂量下也会发生,这引起了对非糖尿病使用的担忧.
科学领域:
- 免疫学 免疫学 免疫学
- 代谢途径 代谢途径
- 细胞生物学 细胞生物学
背景情况:
- 甲胺广泛用于糖尿病,但它对非糖尿病患者的免疫效应尚不清楚.
- 了解甲福明对免疫系统的影响对于评估其更广泛的治疗潜力和安全性至关重要.
研究的目的:
- 在非糖尿病情况下调查甲福尔的免疫安全性.
- 阐明甲胺影响胸细胞发育和存活的机制.
主要方法:
- 利用各种小鼠模型研究甲胺对胸细胞的影响.
- 采用了包括流细胞计,转录组学和代谢分析在内的技术.
- 研究了线粒体功能,AMP激活蛋白激酶 (AMPK) 激活和B细胞淋巴瘤-2 (Bcl-2) 信号通路.
主要成果:
- 甲福明会诱导双阳性胸细胞的亡,从而形成一个由成熟和随后的消除为特征的"选择陷".
- 该机制涉及线粒体功能障碍 (复合I抑制),ATP耗尽和活性氧物种增加.
- 持续的AMPK激活重新定位ERK1/2信号,导致BCL-2抑制和亡,AMPK驱动的代谢途径重塑进一步加剧.
- 即使在治疗次的甲福林剂量 (25 mg/kg) 中也观察到胸腺毒性.
结论:
- 在非糖尿病患者中,由于甲基细胞毒性,甲福明对中央免疫恒温形成风险.
- 观察到的"选择陷"机制凸显了甲福明使用超出其抗糖尿病应用的潜在不良免疫学后果.
- 建议在非糖尿病人群中不分青红白地使用甲福明时谨慎使用.
更多相关视频
08:04Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
Published on: October 23, 2018
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
Oral Hypoglycemic Agents: Biguanides and Glitazones
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
cAMP-dependent Protein Kinase Pathways
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Insulin: The Receptor and Signaling Pathways
